Recce Pharmaceuticals Ltd. (SWB:R9Q) Financings

Recce Pharmaceuticals Ltd.

Financings

RaiseDateIn US dollars
Secured debt facility with warrants
Terms changed: Warrants at A$0.29
Buyers: Avenue Capital Group (lender under the existing secured debt facility)
Use of proceeds: Financial flexibility to support ongoing Phase 3 clinical trial programs
Oct 16, 2026
Share purchase plan of new fully paid ordinary shares (SPP Shares) with free-attaching unlisted options
Update: up to A$4M · A$0.4 a share · Warrants at A$0.6 · Ord Minnett Limited +1
Dealers: Ord Minnett Limited (lead), SP Corporate Advisory Pty Ltd (co-lead)
Insiders: Participating directors can receive SPP Shares; their SPP Options are subject to shareholder approval at the EGM
Use of proceeds: Same purposes as the Placement
Sep 2, 2026US$2.76M
Private placement of new fully paid ordinary shares with free-attaching unlisted options
Announced: A$4M · A$0.4 a share · Warrants at A$0.6 · Ord Minnett Limited +1
Dealers: Ord Minnett Limited (lead), SP Corporate Advisory Pty Ltd (co-lead)
Use of proceeds: Strengthen balance sheet for Middle Eastern licensing deal, clinical trials, IND-enabling activities and working capital
Jun 26, 2026US$2.76M
Private placement of new fully paid ordinary shares
Announced: A$5M · A$0.28 a share
Use of proceeds: Commencement and completion of one of the Phase III clinical trials
Apr 10, 2025US$3.1M
Rights offering of new fully paid ordinary shares
Announced: up to A$10.8M · A$0.28 a share
Insiders: Each of the Directors who are Eligible Shareholders intends to participate in the Entitlement Offer
Use of proceeds: Other programs currently in development by the Company
Apr 10, 2025US$6.7M

Read by 6ix AI from the company's releases